Juravinski Cancer Center
14
1
2
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
Role: collaborator
Financial Toxicity in Breast Cancer Surgery
Role: collaborator
STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer
Role: lead
Assessment of QoL and Outcomes With SBRT for RCC
Role: collaborator
Low Dose Hemi-body Radiation For Recurrent Prostate Cancer
Role: lead
Prostate Boost Irradiation With Stereotactic Body RT (SBRT)
Role: lead
Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis
Role: lead
Stereotactic Body Radiotherapy Boost After Palliative Radiotherapy for Spinal Cord Compression
Role: lead
Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection
Role: lead
Red Blood Cell Transfusion Thresholds and QOL in MDS
Role: collaborator
Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer
Role: lead
MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank
Role: collaborator
Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer
Role: lead
Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. VMAT
Role: lead
All 14 trials loaded